Influence of <em>ABCB1</em> and <em>CYP3A5</em> gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke

Abstract

Questions such as depending on genotyping results for apixaban dosing and implementation of express genotyping in clinical practice remain open for NOACs. Large population studies are required to clarify the clinical significance of genotyping for this drug class.